Literature DB >> 26447188

Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions.

Ciara L Freeman1, Franck Morschhauser2, Laurie Sehn3, Mark Dixon4, Richard Houghton4, Thierry Lamy5, Günter Fingerle-Rowson6, Elisabeth Wassner-Fritsch6, John G Gribben1, Michael Hallek7, Gilles Salles8, Guillaume Cartron9.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26447188      PMCID： PMC4671111          DOI： 10.1182/blood-2015-09-670802

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  22 in total

1.  Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells.

Authors:  Michaela Patz; Polina Isaeva; Nche Forcob; Bianka Müller; Lukas P Frenzel; Clemens-Martin Wendtner; Christian Klein; Pablo Umana; Michael Hallek; Günter Krause
Journal:  Br J Haematol       Date:  2010-12-13       Impact factor: 6.998

2.  Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity.

Authors:  J C Byrd; T Murphy; R S Howard; M S Lucas; A Goodrich; K Park; M Pearson; J K Waselenko; G Ling; M R Grever; A J Grillo-Lopez; J Rosenberg; L Kunkel; I W Flinn
Journal:  J Clin Oncol       Date:  2001-04-15       Impact factor: 44.544

3.  A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies.

Authors:  Laurie H Sehn; Sarit E Assouline; Douglas A Stewart; Joy Mangel; Randy D Gascoyne; Gregg Fine; Susan Frances-Lasserre; David J Carlile; Michael Crump
Journal:  Blood       Date:  2012-03-20       Impact factor: 22.113

Review 4.  Interleukin-6 in sepsis and capillary leakage syndrome.

Authors:  Alexander Krüttgen; Stefan Rose-John
Journal:  J Interferon Cytokine Res       Date:  2011-12-02       Impact factor: 2.607

5.  Rituximab-induced thrombocytopenia: a cohort study.

Authors:  Thijs J Giezen; Aukje K Mantel-Teeuwisse; Maarten J ten Berg; Sabine M J M Straus; Hubert G M Leufkens; Wouter W van Solinge; Toine C G Egberts
Journal:  Eur J Haematol       Date:  2012-07-05       Impact factor: 2.997

6.  Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity.

Authors:  Ekkehard Mössner; Peter Brünker; Samuel Moser; Ursula Püntener; Carla Schmidt; Sylvia Herter; Roger Grau; Christian Gerdes; Adam Nopora; Erwin van Puijenbroek; Claudia Ferrara; Peter Sondermann; Christiane Jäger; Pamela Strein; Georg Fertig; Thomas Friess; Christine Schüll; Sabine Bauer; Joseph Dal Porto; Christopher Del Nagro; Karim Dabbagh; Martin J S Dyer; Sibrand Poppema; Christian Klein; Pablo Umaña
Journal:  Blood       Date:  2010-03-01       Impact factor: 22.113

Review 7.  IL-6/IL-6 receptor system and its role in physiological and pathological conditions.

Authors:  Masahiko Mihara; Misato Hashizume; Hiroto Yoshida; Miho Suzuki; Masashi Shiina
Journal:  Clin Sci (Lond)       Date:  2012-02       Impact factor: 6.124

8.  Endogenous IL-8 acts as a CD16 co-activator for natural killer-mediated anti-CD20 B cell depletion in chronic lymphocytic leukemia.

Authors:  Emilie Laprevotte; Loïc Ysebaert; Christian Klein; Wilfried Valleron; Amandine Blanc; Emilie Gross; Guy Laurent; Jean-Jacques Fournié; Anne Quillet-Mary
Journal:  Leuk Res       Date:  2012-12-20       Impact factor: 3.156

9.  Modulation of cytokine-induced production of IL-8 in vitro by interferons and glucocorticosteroids.

Authors:  Kristina Nyhlén; Chamilly Gautam; Rolf Andersson; Uppugunduri Srinivas
Journal:  Inflammation       Date:  2004-04       Impact factor: 4.092

Review 10.  Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence.

Authors:  Mohit Trikha; Robert Corringham; Bernard Klein; Jean-François Rossi
Journal:  Clin Cancer Res       Date:  2003-10-15       Impact factor: 12.531
View more
  32 in total

1.  Ibrutinib reduces obinutuzumab infusion-related reactions in patients with chronic lymphocytic leukemia and is associated with changes in plasma cytokine levels.

Authors:  Juliana Velez Lujan; Paula A Lengerke-Diaz; Chaja Jacobs; Eider F Moreno-Cortes; Cesar A Ramirez-Segura; Michael Y Choi; Colin McCarthy; Alaina Heinen; Thomas J Kipps; Januario E Castro
Journal:  Haematologica       Date:  2019-05-02       Impact factor: 9.941

2.  GA101 P329GLALA, a variant of obinutuzumab with abolished ADCC, ADCP and CDC function but retained cell death induction, is as efficient as rituximab in B-cell depletion and antitumor activity.

Authors:  Sylvia Herter; Frank Herting; Gunter Muth; Erwin van Puijenbroek; Tilman Schlothauer; Claudia Ferrara; Kevin Brady; Sabine Lang; Marina Bacac; Ekkehard Mössner; Pablo Umana; Christian Klein
Journal:  Haematologica       Date:  2017-10-27       Impact factor: 9.941

3.  Spatially selective depletion of tumor-associated regulatory T cells with near-infrared photoimmunotherapy.

Authors:  Kazuhide Sato; Noriko Sato; Biying Xu; Yuko Nakamura; Tadanobu Nagaya; Peter L Choyke; Yoshinori Hasegawa; Hisataka Kobayashi
Journal:  Sci Transl Med       Date:  2016-08-17       Impact factor: 17.956

4.  Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial.

Authors:  Christopher R Heery; Geraldine O'Sullivan-Coyne; Ravi A Madan; Lisa Cordes; Arun Rajan; Myrna Rauckhorst; Elizabeth Lamping; Israel Oyelakin; Jennifer L Marté; Lauren M Lepone; Renee N Donahue; Italia Grenga; Jean-Marie Cuillerot; Berend Neuteboom; Anja von Heydebreck; Kevin Chin; Jeffrey Schlom; James L Gulley
Journal:  Lancet Oncol       Date:  2017-03-31       Impact factor: 41.316

5.  Bone marrow involvement is a risk factor for infusion-related reactions in patients with follicular lymphoma treated by obinutuzumab.

Authors:  Yosuke Masamoto; Kazuki Taoka; Hiroaki Maki; Mineo Kurokawa
Journal:  Ann Hematol       Date:  2022-10-03       Impact factor: 4.030

6.  Obinutuzumab for the treatment of chronic lymphocytic leukemia and other B-cell lymphoproliferative disorders.

Authors:  Rabih Said; Apostolia M Tsimberidou
Journal:  Expert Opin Biol Ther       Date:  2017-09-11       Impact factor: 4.388

Review 7.  Obinutuzumab for the treatment of indolent lymphoma.

Authors:  Jennifer Edelmann; John G Gribben
Journal:  Future Oncol       Date:  2016-04-27       Impact factor: 3.404

8.  Obinutuzumab-mediated high-affinity ligation of FcγRIIIA/CD16 primes NK cells for IFNγ production.

Authors:  Cristina Capuano; Chiara Pighi; Rosa Molfetta; Rossella Paolini; Simone Battella; Gabriella Palmieri; Giuseppe Giannini; Francesca Belardinilli; Angela Santoni; Ricciarda Galandrini
Journal:  Oncoimmunology       Date:  2017-02-10       Impact factor: 8.110

9.  Obinutuzumab-induced coagulopathy in chronic lymphocytic leukaemia with trisomy 12.

Authors:  H S Walter; S Jayne; P Mensah; F M Miall; M Lyttelton; M J S Dyer
Journal:  Blood Cancer J       Date:  2016-06-17       Impact factor: 11.037

Review 10.  The clinical development of obinutuzumab for the treatment of follicular lymphoma.

Authors:  Barbara Ma; Chaitra Ujjani
Journal:  Cancer Manag Res       Date:  2017-04-10       Impact factor: 3.989
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.